Comparing CPX-351 to Intensive Chemotherapy for Acute Myeloid Leukemia

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase II trial is a randomized, open-label study that compares the efficacy of CPX-351 against conventional intensive chemotherapy in patients with newly diagnosed de novo acute myeloid leukemia (AML) who have intermediate or adverse-risk genetic profiles. The study focuses on patients aged 50 and older, particularly those with specific secondary-type mutations that are associated with poorer outcomes when treated with standard chemotherapy. The primary goal is to evaluate the rate of minimal residual disease (MRD) negative remissions achieved with CPX-351 as both induction and consolidation therapy. The trial aims to provide new therapeutic options for this high-risk patient population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. De novo AML
2. No MRC-defining cytogenetic lesion
3. No t(15;17), t(8;21), inv(16) or t(16;16)
4. No NPM1 gene mutation
5. No FLT3 mutated AML (FLT3 ITD or TKD)
6. Not previously treated except for short course hydroxyurea in patients presenting with high WBC count and/or tumor symptoms,
7. Age ≥ 50 years,
8. Performance status ≤ 2 (ECOG grading),
9. Patient must have adequate organ function as indicated detailed with laboratory values in the section IV of the protocol
10. Female patient of childbearing potential with a negative serum pregnancy test (β-hCG) within 72 hours prior to receiving the first dose of CPX-351 or 7+3. Female patient who is not actively breastfeeding at the time of study entry.
11. Female patient is either post-menopausal, free from menses for \> 2 years, surgically sterilized or willing to use 2 adequate barrier methods of contraception to prevent pregnancy, or agrees to not become pregnant throughout the study, starting with study screening
12. Male patient agrees to use an adequate method of contraception for the duration of the study. Men should be advised not to father a child while receiving CPX-351 or 7+3 and for 3 months after the last dose of study treatment .
13. Patient is available for periodic blood sampling, study related assessments, and appropriate clinical management at the treating institution for the duration of the study.
14. Patient has the ability to understand and willingness to sign an informed consent form indicating the investigational nature of the study.
15. Patient registered to the French Social Security.

Exclusion Criteria:

1. Prior history of documented MDS, MPN or MDS/MPN, tAML
2. Prior history of radiation therapy or chemotherapy for a solid tumor or lymphoma (exceptions to be considered: local radiotherapy for prostate cancer)
3. Patient has active and uncontrolled infection.
4. Patient has uncontrolled intercurrent illness or circumstances that could limit compliance with the study, including but not limited to the following: symptomatic congestive heart failure, unstable angina pectoris, uncontrolled cardiac arrhythmia, pancreatitis, or psychiatric or social conditions that may interfere with patient compliance.
5. Patient is currently participating or has participated in a study with an investigational compound or device within 30 days of initial dosing with study drug.
6. Patient has known human immunodeficiency virus (HIV) infection or HIV-related malignancy.
7. Patient has clinically active hepatitis B or hepatitis C infection.
8. Patient has a known allergy or hypersensitivity to any component of CPX-351, idarubicin or cytarabine.
9. Patient with a "currently active" second malignancy, other than nonmelanoma skin cancer and carcinoma in situ of the cervix, should not be enrolled. Patients are not considered to have a "currently active" malignancy if they have completed therapy for a prior malignancy, are disease free from prior malignancies for \>1 year or are considered by their physician to be at less than 30% risk of relapse.
10. Patients with clinical evidence of CNS leukemia.
11. Cardiac ejection fraction \<50% or considered as abnormal by echocardiography or multi-gated acquisition (MUGA) scan.
12. Patient is pregnant or breastfeeding within the projected duration of the study.

Where it's running

• CHU Amiens Picardie site Sud
  Amiens, France Recruiting
• CH Avignon
  Avignon, France Recruiting
• CHRU Jean Minjoz
  Besançon, France Recruiting
• Centre Hospitalier de Béziers
  Béziers, France Recruiting
• Hôpital Avicenne APHP
  Bobigny, France Recruiting
• Institut d'hématologie de Basse Normandie (IHBN)
  Caen, France Recruiting

Study contacts

• Principal investigator: Thomas Cluzeau, MD — Centre Hospitalier Universitaire de Nice
• Study coordinator: valerie Foussat
• Email: foussat.v@chu-nice.fr
• Phone: +33492034011

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Tailored exercise program to improve quality of life for adults with hematologic cancers

  This pilot trial tests a personalized 16-week exercise program to see if it’s feasible and helpful for adults with acute myeloid leukemia, lymphoma, or multiple myeloma after first-line treatment.

  Recruiting Gruppo Italiano Malattie EMatologiche dell'Adulto · Roma, Rm and 2 other locations · NCT07912684

• Characterization of CD180 Protein Expression in Myeloid Blood C cancers

  This study tests how CD180 is presented on myeloid cancer cells and normal stem cells using existing patient samples from AML cases to see if it could help with diagnosis or monitoring.

  Recruiting University Hospital, Strasbourg, France · Strasbourg · NCT07895901

• Personalized AML: Find biomarkers to predict response to venetoclax

  This study tests whether single-cell analyses can help group AML patients by biology and find biomarkers that predict who will respond to venetoclax.

  Recruiting Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · Milan · NCT07874100

• Low-dose Liposomal Amphotericin B for preventing fungal infections in adults with blood cancers and prolonged neutropenia

  This study tests whether giving a daily 50 mg dose of liposomal amphotericin B can help prevent invasive fungal infections in adults with blood cancers who have prolonged low white blood cell counts.

  Recruiting Haikou Affiliated Hospital of Central South University Xiangya School of Medicine · Hainan, Hainan · NCT07763054

• MAX-40279 with Venetoclax and Azacitidine for unfit newly diagnosed AML

  This study tests MAX-40279 added to venetoclax and azacitidine in older or unfit adults newly diagnosed with AML to see if it is safe and shows activity.

  Recruiting Phase 2 Maxinovel Pty., Ltd. · Tianjin · NCT07743112

• Venetoclax and Azacitidine Consolidation After Remission in Intermediate-Risk AML

  We’re testing if a venetoclax-plus-azacitidine consolidation approach works as well as standard high-dose chemotherapy for adults with intermediate-risk AML who have already achieved remission and are headed to stem cell transplant.

  Recruiting Phase 2 The First Affiliated Hospital of Soochow University · Suzhou, Jiangsu · NCT07672262

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.